Blue Earth Diagnostics, a renowned company in PET radiopharmaceutical development, announced the results of a post-hoc analysis from the Phase 3 SPOTLIGHT trial. The study evaluated the use of POSLUMA injection for detecting prostate cancer recurrence in patients who had undergone radical prostatectomy and had low PSA levels.
The analysis revealed high detection rates for POSLUMA in the pelvic region, particularly in patients with PSA levels below 1 ng/mL and 0.5 ng/mL. This suggests that POSLUMA is effective in detecting recurrence in its early stages.
POSLUMA, approved by the FDA, aids in the visualization of PSMA-positive prostate cancer lesions. It provides essential information to guide treatment decisions for men with suspected recurrence who may benefit from curative salvage therapy.
The high affinity of POSLUMA for PSMA allows for accurate detection despite potential interference from activity in the urinary bladder and ureters. Unlike other PSMA PET radiopharmaceuticals, POSLUMA’s image assessment is not significantly impacted by urinary activity in the majority of patients, ensuring accurate interpretation.
POSLUMA’s enhanced detection capabilities make it a valuable tool for managing prostate cancer. Detecting recurrence early and providing reliable information helps guide treatment and improve patient outcomes.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Ferry, a computer data scientist, focuses on the latest clinical trial industry news and trends.
